Previous 10 | Next 10 |
– Study provides therapeutic rationale for SLN124, Silence’s clinical candidate for polycythemia vera and other hematological disorders Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biote...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management...
2023-03-28 08:11:00 ET Silence Therapeutics ( NASDAQ: SLN ) is acquiring back exclusive worldwide rights to two siRNA drug targets for complement-mediated diseases from Mallinckrodt Pharmaceuticals ( NYSE: MNK ). Under the agreement, London-based Silence will ...
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people...
Deal gives Silence exclusive worldwide rights to two siRNA complement assets Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing d...
2023-03-15 13:49:06 ET Silence Therapeutics plc (SLN) Q4 2022 Earnings Conference Call March 15, 2023 08:00 ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhon...
Company to host fourth quarter conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s live...
2023-03-13 23:58:45 ET Summary Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential upside, supported by its robust pipeline, strateg...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will r...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, Pres...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...